When I evaluate a Povidone K17 manufacturer in China, I first verify three things: whether the material is genuinely suitable for the intended application, whether the documentation supports the target market, and whether the supplier can provide consistent bulk batches. Povidone K17 is a low-viscosity grade of polyvinylpyrrolidone, commonly identified by a K-value around 17, although the exact acceptable range depends on the supplier specification and applicable pharmacopoeia. For pharmaceutical buyers, a reliable purchasing decision should therefore include a current specification sheet, certificate of analysis, safety documentation, sample approval, packaging details, and a realistic production lead time.
In this guide, I explain how B2B buyers can compare Chinese Povidone K17 suppliers, match the grade to an application, review quality documents, and reduce sourcing risk before placing a bulk order. I also distinguish between information that can be used for initial screening and information that must be confirmed directly with the manufacturer.
This guide is intended for pharmaceutical manufacturers, contract manufacturers, formulation developers, distributors, importers, and purchasing teams sourcing Povidone K17 from China. It is especially useful when the buyer needs material for a regulated market, a new formulation, or a repeat-production program. It can also help technical teams compare suppliers that use different product names or specification formats.
I recommend using this guide before requesting a quotation because price alone does not show whether a grade is suitable. A lower-priced material may require additional qualification, extra testing, different packaging, or a longer regulatory review. The right supplier is the one that can connect product quality, documentation, production control, and commercial terms.
Povidone, also called polyvinylpyrrolidone or PVP, is a water-soluble polymer identified by CAS No. 9003-39-8. “K17” refers to a K-value classification associated with the polymer’s solution viscosity and molecular-size range; it should not be treated as an exact molecular weight value. In practice, buyers should compare the supplier’s stated K-value method, test conditions, limits, and batch results rather than relying only on the grade name.
Povidone is used in several technical roles, including binder, solubilizer, film-forming aid, stabilizer, and processing aid. Its suitability depends on concentration, solvent system, active ingredient, dosage form, processing conditions, and the required regulatory standard. The United States Food and Drug Administration’s Inactive Ingredient Database is one useful reference for checking whether povidone has appeared in approved drug products, but buyers must still evaluate route, dosage form, maximum use level, and local regulatory requirements.
The K-value gives buyers a practical way to distinguish grades with different viscosity behavior. A K17 product is generally selected when a formulation needs the functional benefits of povidone without the higher viscosity associated with some higher-K grades. However, viscosity results can be affected by concentration, solvent, temperature, measurement method, and instrument settings.
For this reason, I do not recommend approving a supplier based on “K17” alone. The technical file should state the test method and conditions, such as polymer concentration, temperature in degrees Celsius, spindle or instrument information where relevant, and the acceptance range. The supplier should also explain whether the stated value is a release specification, a typical value, or a compendial requirement.
Povidone K17 may be considered for oral solid dosage forms, liquid formulations, topical products, and other pharmaceutical applications where a low-viscosity, water-soluble polymer is appropriate. In tablets, povidone grades can function as binders, but the final result depends on binder concentration, granulation method, active ingredient properties, and drying conditions. In liquids, compatibility and clarity should be assessed with the active ingredient, solvent system, preservatives, and container materials.
For a regulated pharmaceutical application, I recommend requesting pharmaceutical-grade documentation rather than assuming that an industrial or cosmetic grade is interchangeable. The buyer should confirm applicable pharmacopoeial compliance, elemental impurity controls, residual solvent information, microbiological limits, and change-control procedures. The final acceptance decision should be made by the buyer’s quality and regulatory teams.
In personal-care formulations, povidone can contribute film formation, binding, solubilization, or texture modification. The correct grade depends on the product type, desired sensory profile, water content, alcohol content, and compatibility with other polymers. A supplier should provide a specification that addresses appearance, identification, viscosity or K-value, moisture, ash or residue-related parameters, and microbiological expectations where applicable.
Some buyers use povidone in technical formulations, coatings, adhesives, printing systems, or other water-compatible applications. These projects may prioritize viscosity consistency, color, solubility, packaging, and cost rather than pharmaceutical compliance. I recommend separating technical-grade requirements from pharmaceutical-grade requirements at the quotation stage so the supplier does not offer a lower documentation level than the project needs.
| Buyer Requirement | What to Check | Why It Matters |
|---|---|---|
| K-value grade | Target value, permitted range, and test method | Helps control viscosity and formulation behavior |
| Regulatory grade | USP/NF, Ph. Eur., BP, or other applicable standard | Supports market-specific qualification |
| Physical form | Powder appearance, color, particle characteristics, and solubility | Influences handling and processing |
| Impurity control | Residual solvents, elemental impurities, and related substances | Important for risk assessment and regulatory review |
| Microbiological quality | Total counts and specified organism requirements | Relevant to pharmaceutical, cosmetic, and sensitive formulations |
USP-NF and the European Pharmacopoeia are authoritative references, but the applicable monograph and edition should be confirmed for the destination market. A supplier’s statement that a product is “pharma grade” is not a substitute for reviewing the actual certificate and current specification. I also recommend checking whether the certificate reports numerical batch results or only pass/fail conclusions.
Before contacting a manufacturer, I define the application, dosage form or product type, annual volume, destination country, and required regulatory standard. I also identify whether the buyer needs development samples, commercial packaging, or validated repeat supply. This information allows the supplier to recommend a suitable documentation package instead of sending a generic quotation.
A basic request should include the product specification, recent certificate of analysis, safety data sheet, technical data sheet, product description, packaging information, shelf-life statement, and storage conditions. For regulated projects, I may also request manufacturing-site information, change-notification procedures, allergen or GMO statements where relevant, residual-solvent data, elemental-impurity information, and declaration of compliance with the buyer’s required standard.
The documents should be internally consistent. The product name, batch number, manufacturing date, retest or expiry date, test methods, units, and acceptance limits should match across the certificate and specification. If a supplier cannot explain a difference between documents, I treat that as a qualification issue rather than a minor administrative detail.
Link to Yuking
Sample testing should use the buyer’s actual formulation or a representative laboratory method whenever possible. For viscosity-related evaluation, the buyer should control concentration and temperature, because a result at 20°C may not be directly comparable with a result at 25°C. I recommend recording sample identification, preparation time, mixing conditions, filtration, appearance, dissolution time, and measured viscosity or K-value.
A practical first-stage sample may be 100 g to 1 kg, depending on the application and laboratory method, but the required quantity should be agreed with the supplier. Sample approval does not replace commercial-batch qualification. The buyer should later compare at least one commercial lot with the approved sample using the same test method.
For bulk purchasing, I ask about standard batch size, available monthly capacity, production scheduling, packaging formats, palletization, container loading, and export experience. Common industrial packaging may include 20 kg or 25 kg bags, but actual packaging should be confirmed because moisture protection and handling requirements can vary. I also request the minimum order quantity, sample policy, lead time, payment terms, and shipment documentation before comparing offers.
A supplier may quote a competitive unit price but still create risk through inconsistent lead times or limited production visibility. I therefore ask whether the quoted lead time is based on ready stock, scheduled production, or a new manufacturing slot. For repeat programs, a written forecast and agreed delivery schedule can be more valuable than a small initial price reduction.
I also consider whether the supplier can support technical questions after the order. A responsive technical contact can help resolve differences in test methods, packaging condition, or dissolution performance before they become production delays. For B2B purchasing, communication quality is part of supply reliability.
Povidone K17 pricing can vary with grade, documentation, order volume, packaging, destination, payment terms, and raw-material conditions. I avoid comparing prices until I confirm that the quotations refer to the same specification and the same delivery basis, such as EXW, FOB, or CIF. A quotation should also state whether testing, special packaging, sample preparation, and export documents are included.
MOQ is not universal and may differ between stocked material and made-to-order production. A smaller trial order may carry a higher unit cost, while a larger order may require additional storage or a longer production schedule. I recommend asking for at least three quantities, such as sample, trial, and commercial volume, so the purchasing team can compare total landed cost rather than unit price alone.
Lead time should be divided into document review, sample preparation, production, testing, packing, and shipment. For example, a buyer may need separate estimates for a 1 kg laboratory sample, a 25 kg trial order, and a full-container shipment. These figures are planning examples only; the supplier must confirm actual timing based on inventory and production status.
The FDA Inactive Ingredient Database can support an initial regulatory review for pharmaceutical excipients, while the United States Pharmacopeia and European Pharmacopoeia provide recognized compendial references. These sources do not approve a particular supplier or guarantee that a specific batch is suitable. I use them as reference points, then rely on the supplier’s current documents and the buyer’s own qualification process.
“K17” is a useful starting point, but it does not describe every quality attribute. Two suppliers may use similar grade names while applying different test methods, limits, moisture controls, or packaging systems. I always compare the full specification and certificate rather than the product label alone.
A generic certificate may not show the actual batch number or numerical test results. This limits the buyer’s ability to verify consistency and traceability. For qualification, I prefer a batch-specific certificate that identifies the tested lot and the applicable methods.
A document package acceptable for one market may be incomplete for another. Buyers should identify requirements for the United States, European Union, United Kingdom, or other destination before requesting a final quotation. The supplier can then confirm which documents are available and which must be arranged separately.
At Yuking, I approach Povidone K17 sourcing as a specification-matching process rather than a simple price request. I can organize an initial review around application, target market, required grade, documentation, packaging, quantity, and delivery destination. Where the buyer has an existing specification, I recommend sending it for a point-by-point comparison before sample approval.
For a new project, I can help structure the inquiry into technical and commercial requirements. These may include K-value range, applicable pharmacopoeial reference, certificate format, sample quantity, packaging preference, MOQ, annual demand, and expected delivery schedule. Final availability, documentation, and lead time should be confirmed against the current product and production plan.
The best Povidone K17 manufacturer in China is not necessarily the supplier with the lowest quoted price. I recommend choosing the supplier that can demonstrate grade suitability, transparent test methods, complete documentation, consistent batch control, and realistic bulk-delivery capability. The buyer should approve the specification and sample before treating the product as qualified for commercial production.
The next step is to prepare a structured inquiry containing the application, destination market, required standard, annual volume, sample quantity, packaging needs, and delivery terms. Send that information to Yuking for a product and supply review, then compare the returned specification, certificate, MOQ, lead time, and commercial offer with other qualified suppliers. This process helps convert a generic Povidone K17 quotation into a controlled and traceable B2B sourcing decision.
Want more information on povidone k17 manufacturer china? Feel free to contact us.